Coya Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Coya Therapeutics, Inc. (COYA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $4.77 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-11
- Coya Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $4.79, a 20.96% decline year-over-year.
- Coya Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $6.06, a 0.33% increase year-over-year.
- Coya Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $6.04, a 56.88% increase year-over-year.
- Coya Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.85.
- Coya Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $6.04, a 13.09% decline from fiscal 2024.
- Coya Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $6.95, a 78.21% increase from fiscal 2023.
- Coya Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $3.90, a 12.07% increase from fiscal 2022.
- Coya Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $3.48.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.77 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $4.79 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $6.04 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $6.04 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $6.06 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $6.06 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $6.95 10-K · filed 2025-03-18 | |||
| 2024-09-30 | $6.95 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $6.97 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $6.04 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $3.90 10-K · filed 2024-03-19 | |||
| 2023-09-30 | $3.90 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | $3.89 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $3.85 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $3.48 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |